Protocol M23-716: A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacyand safety of upadacitinib in adult and adolescent subjects with severe alopecia areata Protocol Date:01June 2023

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.